| 1 |
34638401 | MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. | 2021 Sep 30 |
2 |
| 2 |
32306000 | [Establishment and gene expression analysis of drug-resistant cell lines in hepatocellular carcinoma induced by sorafenib]. | 2020 Apr 18 |
2 |
| 3 |
29188798 | Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling. | 2018 Mar |
1 |
| 4 |
29251327 | Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. | 2018 Feb |
1 |
| 5 |
29470830 | Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1. | 2018 Jun |
1 |
| 6 |
29484394 | Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line. | 2018 Apr |
2 |
| 7 |
29693132 | Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins. | 2018 Jun |
1 |
| 8 |
28454244 | Proliferation of sphere-forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine. | 2017 Mar |
1 |
| 9 |
26769852 | MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. | 2016 Feb 9 |
2 |
| 10 |
26847681 | Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. | 2016 Dec |
1 |
| 11 |
26964667 | Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. | 2016 Mar 11 |
1 |
| 12 |
27367026 | Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway. | 2016 Aug 2 |
1 |
| 13 |
25289088 | Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells. | 2014 Nov |
2 |
| 14 |
23468839 | α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy. | 2013 |
1 |
| 15 |
23769634 | PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. | 2013 Nov |
1 |
| 16 |
21604268 | Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. | 2012 Apr |
1 |
| 17 |
21617941 | Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. | 2012 Feb |
3 |
| 18 |
21858812 | Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. | 2012 Aug 1 |
1 |
| 19 |
22265862 | Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. | 2012 Jun 1 |
1 |
| 20 |
19913321 | Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. | 2010 Jan |
3 |
| 21 |
20432459 | Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. | 2010 Aug |
1 |
| 22 |
17178882 | Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | 2006 Dec 15 |
4 |